Paul B Manning bought $3.0M of CADL
director at Candel Therapeutics, Inc.. 550,458 shares at an average of $5.45, traded Feb 23, 2026, filed Feb 26, 2026.
Score components
- +15RoleDirector
- +25Trade size$3.0M at market
- +6Relative to holdingsHoldings up 25%
- +8Price context55% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -6.6%, 3m +57.1%, 6m +167.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-078246, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 23, 2026 | POpen-market purchase Common Stockindirect: By Paul B. Manning Revocable Trust | +550,458 | $5.45 | $3.0M | 2,763,527 | Feb 26, 2026 |
Related signals
Other insiders at Candel Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | Candel Therapeutics, Inc. | Paul Peter Tak Chief Executive Officer | $3.2M 280,245 shares | -71% | |
| 4Weak | Candel Therapeutics, Inc. | Seshu Tyagarajan Chief Technology Officer | $84k 7,000 shares | -8% | |
| 21Weak | Candel Therapeutics, Inc. | Francesca Barone Chief Scientific Officer | $236k 23,447 shares | -23% | |
| 11Weak | Candel Therapeutics, Inc. | Seshu Tyagarajan Chief Technology Officer | $70k 7,000 shares | -8% | |
| 0Weak | Candel Therapeutics, Inc. | William Garrett Nichols Chief Medical Officer | $6,540 937 shares | -2% | |
| 0Weak | Candel Therapeutics, Inc. | William Garrett Nichols Chief Medical Officer | $3,936 781 shares | -1% | |
| 14Weak | Candel Therapeutics, Inc. | Francesca Barone Chief Scientific Officer | $282k 32,146 shares | -25% | |
| 38Weak | Candel Therapeutics, Inc. | Paul Peter Tak Chief Executive Officer | $230k 26,172 shares | -10% | |
| 21Weak | Candel Therapeutics, Inc. | William Garrett Nichols Chief Medical Officer | $397k 45,316 shares | -46% | |
| 21Weak | Candel Therapeutics, Inc. | Charles Schoch See Remarks | $44k 5,000 shares | -12% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.